Stereotactic radiotherapy for prostate cancer: A review and future directions

Table 2 Summary of genitourinary toxicities for included stereotactic body radiotherapy trials

Study	Acute			Late			Clinical notes
	Gr. 1	Gr. 2	Gr. ≥ 3	Gr. 1	Gr. 2	Gr. ≥ 3
Madsen (IJROBP, 2007)	28%	21.50%	1 tot	25%	20%	0%	Gr. 3 event was urinary obstruction that resolved
Pham (IJROBP, 2010)				22.50%	12.50%	2.50%	All toxicities resolved
Boike (JCO, 2011)1	28.80%	22.20%	0%	13.30%	8.80%	2 tot	Gr. 3 events due to dysuria and cystitis
Katz (BMC Urol, 2010)1	74.60%	4.60%	0%	4.70%	5.10%	1 tot
Jabarri (IJROBP, 2012)	29%	42%	0%	1 tot	8%	2 tot	One case each of urge incontinence and irritation requiring catheterization
King (IJROBP, 2012)1	Not reported	Not reported	Not reported	22.80%	5.30%	2 tot	Gr. 3 patients both underwent repeated urologic instrumentation for post-SBRT dysuria
McBride (Cancer, 2012)	59%	19%	0%	17%	17%	1 tot	Gr. 3 event was urinary obstruction requiring TURP
Anwar (Rad Oncol, 2016)	48%	37%	0%	21%	25%	1 tot	Gr. 3 event was urinary obstruction
Mantz (Fontiers Rad Oncol, 2014)	32.3% frequency, 16.6% dysuria, 7.8% retention		2 tot	19.6% frequency, 2.9% dysuria, 4.9% retention		0%	Gr. 3 events were urinary frequency
Hannan (Eur J Cancer, 2016)1	48.40%	22.00%	0%	24.20%	20.90%	5.50%	1 late Gr. 4 event (cystitis requiring ureteroileal diversion)
Freeman (Rad Oncol, 2011)	Not reported	Not reported	Not reported	25%	7%	1 tot	Gr. 3 event after repeated urologic instrumentation
Davis (Cureus, 2015)	19%/3%/3%2	2%/1%/1%2	0%	25%/4%/5%2	8%/2%/2%2	0%

¹Aggregate values for all cohorts;

²Notation as follows: urinary frequency/urinary retention/cystitis. TURP: Transurethral resection of the prostate.